ECONOMIC DEVELOPMENT:
Can California Protect a Bright Source of Job GrowthPodcast: October 17, 2011
California’s industrial biotechnology sector has been a bright spot of job growth at a difficult economic time, according to a new survey from two trade associations within the state. The groups hope to use the report to convince policymakers that California needs to take steps to grow and retain the industry or risk losing it. We spoke to Gail Mederis, CEO of BayBio, about the report, what actions the state should take, and whether the real threat of these jobs going elsewhere comes from places like Brazil, rather than Nevada. Read More
Emerging Markets
- Bayer Launches $860 Million Joint Venture with Russia’s Yunona Holdings
Russian government continues push to revamp its pharmaceutical and medical industries. Read More
Monthly
- The November 2011 Issue of The Burrill Report
Focus: Management Read More
Treatments
- Researchers Correct Sickle Cell Disease in Mice
Protein therapy shows promise for eliminating symptoms of the blood disorder. Read More
Venture Capital
- Medical Device Developers Attract Cash
Venture capital increases its funding of medical technology. Read More
Economic Development
- Planning for Wild Success
Feds turn to the public seeking ideas for building biotech’s role in the economy. Read More
AgBio
- Europe Warned on Slow Pace of GM Crop Approvals
Industry organization says backlog will impact EU food security. Read More
Trials and Tribulations
- NICE Says Cost of Bristol-Myers Melanoma Drug Too High
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
Deals
- GlycoMimetics Inks Deal with Pfizer for Rare Disease Drug
Treatment for complication of sickle cell disease could net biotech up to $340 million. Read More
Research
- Sing for Your Supper
NIH chief tries to inspire a chorus. Read More
Early-Stage Finance
- Former Cougar Biotechnology CEO Seeks to Repeat Success with Puma
With $55 million from former investors, Auerbach licenses Pfizer cancer drug. Read More
- The Burrill Report (October 17, 2011): Can California Protect a Bright Source of Job Growth
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
November 2011
Download a free copy of the November 2011 issue of The Burrill Report. This month's focus is on personalized medicine.
Click here to download.
Achim Diedenhofen, founder and partner of the consulting firm Executive Insight, discusses Germany's new drug reorganization act, what it means to pharmaceutical revenues, and how companies will need to think about rolling out their drugs in Europe going forward.
Finance Scorecard
Filed IPOs
Completed IPOs
PDUFA Dates
Drug Approvals
Burrill Indices
Biggest Movers
Pharmaceutical Product Development, or PPD, is being taken private by affiliates of the Carlyle Group and Hellman & Friedman in an all cash deal valued at $3.9 billion.
.jpg)
.gif)
